Can you provide the last earnings date for AKERO THERAPEUTICS INC?
AKERO THERAPEUTICS INC (AKRO) last reported earnings on 11/7/2025.
NASDAQ:AKRO • US00973Y1082
Past quarterly earnings results for AKERO THERAPEUTICS INC (AKRO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.98 | -0.94 | -4.15% | 6.67% | - | - | ||
| Q2 2025 | -0.86 | -0.93 | 7.14% | -6.17% | - | - | ||
| Q1 2025 | -0.90 | -0.99 | 9.09% | - | - | - | ||
| Q4 2024 | -0.99 | -1.18 | 15.77% | - | - | - | ||
| Q3 2024 | -1.05 | -0.92 | -13.96% | -47.89% | - | - | ||
| Q2 2024 | -0.81 | -0.92 | 11.64% | -35.00% | - | - | ||
| Q1 2024 | -0.90 | -0.97 | 7.40% | -63.64% | - | - | ||
| Q4 2023 | -0.99 | -0.88 | -12.70% | -102.04% | - | - | ||
| Q3 2023 | -0.71 | -0.69 | -2.18% | 22.83% | - | - | ||
| Q2 2023 | -0.60 | -0.64 | 6.33% | 22.08% | - | - | ||
| Q1 2023 | -0.55 | -0.69 | 19.76% | 25.68% | - | - | ||
| Q4 2022 | -0.49 | -0.81 | 39.80% | 47.31% | - | - | ||
| Q3 2022 | -0.92 | -0.75 | -22.22% | -31.43% | - | - | ||
| Q2 2022 | -0.77 | -0.87 | 11.81% | 7.23% | - | - | ||
| Q1 2022 | -0.74 | -0.81 | 9.09% | -72.09% | - | - | ||
| Q4 2021 | -0.93 | -0.83 | -11.42% | -8.14% | - | - | ||
| Q3 2021 | -0.70 | -0.93 | 24.59% | -11.11% | - | - | ||
| Q2 2021 | -0.83 | -0.74 | -12.50% | -45.61% | - | - | ||
| Q1 2021 | -0.43 | -0.93 | 53.60% | -2.38% | - | - | ||
| Q4 2020 | -0.86 | -0.60 | -42.56% | - | - | - | ||
| Q3 2020 | -0.63 | -0.66 | 4.49% | - | - | - | ||
| Q2 2020 | -0.57 | -0.63 | 9.87% | - | - | - | ||
| Q1 2020 | -0.42 | -0.62 | 32.72% | - | - | - |
Notes
AKERO THERAPEUTICS INC (AKRO) last reported earnings on 11/7/2025.
AKERO THERAPEUTICS INC (AKRO) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, AKERO THERAPEUTICS INC (AKRO) has beaten EPS estimates in 3 out of 4 releases.